Your session is about to expire
← Back to Search
CT1812 for Lewy Body Dementia (COG1201 Trial)
COG1201 Trial Summary
This trial tests whether the study drug is better than placebo at improving thinking and memory in people with mild to moderate dementia with Lewy bodies.
COG1201 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCOG1201 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.COG1201 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a diagnosis of a specific type of dementia, not Alzheimer's.I have a condition like ALS affecting my nervous system.I do not have infections or conditions like hypothyroidism affecting my brain.My recent brain scans are consistent with DLB diagnosis and show no major issues.My condition is stable and won't affect the trial's outcome.I do not have a major psychiatric condition like schizophrenia, bipolar disorder, or severe depression.I have a seizure disorder.I am between 50-85 years old and likely have Dementia with Lewy Bodies.I have no other brain conditions affecting my thinking skills besides DLB.
- Group 1: CT1812 300 mg
- Group 2: CT1812 100 mg
- Group 3: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any qualifications for participating in this clinical experiment?
"This clinical trial aims to enroll 120 patients with lewy body disease, aged 50 and above. Those interested should have a caregiver/study partner that can assist them throughout the study, men willing to use contraception methods or women of non-childbearing age, be able to undergo lumbar puncture tests at specified times during the trial period, possess 8 years of formal education or more, reside in their own home or an assisted living facility,, demonstrate general healthiness as well as adequate mobility vision and hearing for compliance with testing procedures., understand all aspects of the study before providing written consent., and finally meet criteria for probable Dementia"
What is the overall scope of this investigation?
"Currently, 32 medical centres are participating in this study. These sites can be found in Chapel Hill, Winter Park and Lexington as well as 29 other cities. If you decide to enrol in the trial, it is recommended that you choose a location near your residence to reduce travel expenditure."
Does this experiment offer enrollment to individuals who are over five decades of age?
"Qualified applicants for this clinical trial must be aged between 50 to 85. For those below 18, there are 25 seperate trials and 399 alternate studies available to people over 65 years old."
What is the total participant count for this clinical research endeavor?
"The trial sponsor, Cognition Therapeutics, will be initiating the study from two different sites: UNC Department of Neurology in Chapel Hill, North carolina and Charter Research in Winter Park, Florida. To commence research operations a total of 120 suitable participants must be enrolled."
What potential risks have been associated with 100 mg of CT1812?
"Our experts at Power have given CT1812 100 mg a rating of 2, indicating that there is some evidence on its safety but none regarding its efficacy."
Are there any opportunities for individuals to be enrolled in this experimental protocol?
"Affirmative. Clinicaltrials.gov displays that the medical study, which was initially posted on June 22nd 2022, is presently looking for participants. A total of 120 individuals are needed to be enrolled from 32 separate clinical sites."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger